Dishman Carbogen, Client to Invest CHF 25M to Expand Swiss Sites

10 Jun 2025 CW Team

The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC), enabling CARBOGEN AMCIS to meet rising global demand. As part of the agreement, both facilities will see significant equipment and infrastructure enhancements, including:

Aarau site: installation of 850-litre reactors and 0.4 m² agitated filter dryers with supporting equipment. Completion is expected by Q1 2027.
Neuland site: installation of 850-litre reactors and 0.4 m² agitated filter dryers with auxiliary systems. Completion is anticipated by Q3 2027.

This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021 to develop a site extension at the Bubendorf site in Switzerland, reinforcing the strength of the relationship and their shared commitment to long-term growth.

“This expansion demonstrates our ability to scale alongside our customers, responding to the increasing demand for complex and high-value compounds such as ADC drug linkers,” said Stephan Fritschi, CEO at CARBOGEN AMCIS. “We’re proud to continue building on our strong trust and technical collaboration foundation.”

CARBOGEN AMCIS is recognised for its robust capabilities in handling highly potent compounds, offering end-to-end support from process development to commercial supply. The new investments will further strengthen the company’s infrastructure to deliver high-quality manufacturing services in line with cGMP and global regulatory expectations.

“By investing in both Aarau and Neuland, we’re ensuring that our infrastructure keeps pace with our customers’ ambitions,” said Carl Baker, Vice President Business Unit Drug Substance. “These upgrades will allow us to seamlessly manage increased volumes while maintaining the operational excellence and containment controls required for highly potent APIs and advanced therapies.”

With facilities across Switzerland, France, the UK, the Netherlands, and China, CARBOGEN AMCIS continues to expand its global footprint while delivering flexible, integrated CDMO solutions to pharmaceutical and biopharmaceutical innovators worldwide.

The Company’s subsidiary, CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, is pleased to announce a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland.The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC), enabling CARBOGEN AMCIS to meet rising global demand. As part of the agreement, both facilities will see significant equipment and infrastructure enhancements, including:Aarau site: installation of 850-litre reactors and 0.4 m² agitated filter dryers with supporting equipment. Completion is expected by Q1 2027.Neuland site: installation of 850-litre reactors and 0.4 m² agitated filter dryers with auxiliary systems. Completion is anticipated by Q3 2027.This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021 to develop a site extension at the Bubendorf site in Switzerland, reinforcing the strength of the relationship and their shared commitment to long-term growth.“This expansion demonstrates our ability to scale alongside our customers, responding to the increasing demand for complex and high-value compounds such as ADC drug linkers,” said Stephan Fritschi, CEO at CARBOGEN AMCIS. “We’re proud to continue building on our strong trust and technical collaboration foundation.”CARBOGEN AMCIS is recognised for its robust capabilities in handling highly potent compounds, offering end-to-end support from process development to commercial supply. The new investments will further strengthen the company’s infrastructure to deliver high-quality manufacturing services in line with cGMP and global regulatory expectations.“By investing in both Aarau and Neuland, we’re ensuring that our infrastructure keeps pace with our customers’ ambitions,” said Carl Baker, Vice President Business Unit Drug Substance. “These upgrades will allow us to seamlessly manage increased volumes while maintaining the operational excellence and containment controls required for highly potent APIs and advanced therapies.”With facilities across Switzerland, France, the UK, the Netherlands, and China, CARBOGEN AMCIS continues to expand its global footprint while delivering flexible, integrated CDMO solutions to pharmaceutical and biopharmaceutical innovators worldwide.

Infrastructure Urban

30 May 2026

Panasonic Showcases Connected Display Solutions

Panasonic Life Solutions India showcased its integrated display, projection, broadcast and communication technologies at Panasonic Tech Summit 2026 in New Delhi. Hosted through its System Solutions Division, the two-day event highlighted connected technology solutions for education, healthcare, retail, transportation, corporate offices and entertainment.The summit, themed ‘Turning Technology into Value’, featured experience-led zones covering QSR, retail, transit, corporate offices, healthcare, education, security, projection, home theatre and professional displays. Panasonic also introduc..

Infrastructure Transport

30 May 2026

Kapsch to Deliver India’s First C-ITS Project

"Kapsch TrafficCom will deliver India’s first Cooperative Intelligent Transport Systems project on a key expressway near New Delhi. The project will be implemented with Superwave Communication And Infrasolution Limited to demonstrate how connected mobility can improve road safety and traffic efficiency.The pilot will use real-time connectivity and AI-enabled situational awareness to support road users, especially in high-risk areas such as temporary work zones. Drivers will receive alerts on roadworks, maintenance vehicles, hazardous locations, traffic queues and temporary virtual signage di..

Infrastructure Urban

30 May 2026

Eurobond Net Profit Rises 44 Per Cent

Euro Panel Products, the parent company of Eurobond, reported a 44.13 per cent year-on-year rise in net profit for FY25–26. The company’s revenue from operations grew 18.91 per cent to Rs 503.20 crore, compared to Rs 423.18 crore in the previous financial year.The company’s full-year EBITDA stood at Rs 56.67 crore, marking a 31.82 per cent increase. Profit after tax rose to Rs 26.56 crore, while net worth increased 20.15 per cent to Rs 160.07 crore. Earnings per share for the year stood at Rs 10.84.Divyam Rajesh Shah, Whole Time Director and CFO, Euro Panel Products, said the company’s..